• Mark Terry
• 05 Apr, 2021

NeuroRx announced that Zyesami (aviptadil) met the primary endpoint of its Phase IIb/III trial, showing a meaningful survival benefit in critical COVID-19. They also indicated plans to initiate a trial of inhaled Zyesami for patients with moderate and severe COVID-19, and the drug was included in the I-SPY clinical trial platform for COVID-19 respiratory failure.
Read more...